Sionna Therapeutics, Inc. Investigation
Company: Sionna Therapeutics, Inc.
Ticker: (NASDAQ) SION
How to Check Whether You May Be Eligible in the Sionna Therapeutics, Inc. Investigation
Investigation Details
Sionna Therapeutics shares collapsed approximately 92% after the Company disclosed that its Phase 2a PreciSION CF trial of SION-719 failed to achieve its key activity endpoint and that it would not advance the candidate as an add-on therapy.
According to the Company's disclosure, SION-719 -- administered on top of standard of care -- produced a placebo-adjusted sweat chloride change of -1.0 mmol/L, with a p-value of 0.7. Sionna stated it would not advance SION-719 as an add-on therapy. The decline did not follow an apparent liquidity shortfall: Sionna reported approximately $268.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, and a second-quarter net loss of $29.9 million.
Sionna's NBD1 stabilizer programs are central to its cystic fibrosis pipeline. The Company's FY2025 Form 10-K stated that it was "substantially dependent on the success of at least one of our nucleotide binding domain 1 ('NBD1') stabilizers." The investigation concerns whether SION investors received adequate disclosure regarding the Company’s reliance on its NBD1 stabilizer programs and the risks associated with the SION-719 program.